Pulmatrix (NASDAQ:PULM) Announces Earnings Results

Pulmatrix (NASDAQ:PULM – Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.00) by $1.66, FiscalAI reports.

Pulmatrix Stock Up 7.0%

PULM traded up $0.09 during midday trading on Monday, hitting $1.38. The company had a trading volume of 18,417 shares, compared to its average volume of 39,731. The stock’s 50 day moving average price is $1.46 and its 200 day moving average price is $1.66. Pulmatrix has a 52 week low of $1.06 and a 52 week high of $4.98. The company has a market capitalization of $5.04 million, a price-to-earnings ratio of -1.25 and a beta of 1.95.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmatrix in a research report on Thursday. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Pulmatrix presently has an average rating of “Sell”.

View Our Latest Analysis on Pulmatrix

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies. Its proprietary iSPERSE technology is designed to deliver dry-powder medicines to the lungs, and the company’s work has included treatments for respiratory diseases as well as medicines delivered through the lungs for other conditions. Among its drug candidates, PUR1900 is an inhaled formulation of itraconazole being developed for allergic bronchopulmonary aspergillosis, a lung condition associated with fungal sensitivity.

Read More

Earnings History for Pulmatrix (NASDAQ:PULM)

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.